REG - Renalytix PLC - Cancellation of Ordinary Shares & TVR

RenalytixAnnouncement

06/11/2024 14:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241106:nRSF2208La&default-theme=true

RNS Number : 2208L  Renalytix PLC  06 November 2024

Renalytix plc

("Renalytix" or the "Company")

 

Cancellation of Ordinary Shares

Total Voting Rights

 

LONDON and NEW YORK, 6 November 2024 - Renalytix plc (LSE: RENX) (OTCQB:
RNLXY), an artificial intelligence-enabled in vitro diagnostics company,
focused on optimizing clinical management of kidney disease to drive improved
patient outcomes and advance value-based care, announces that, following the
Placing and Subscription undertaken by the Company which was announced on 30
September 2024 (the "Fundraising Announcement"), one of the subscribers is
limiting his Subscription in the Fundraise to £281,955, which is 2,422,723
shares or £218,045 short of his allocated amount. In addition, 8,877 shares
have not been settled with an accounts payable and debt holder which equates
to £798.93.

 

Cancellation of Ordinary Shares and Total Voting Rights

 

The Company will therefore cancel 2,431,600 Ordinary Shares at or around 8.00
am tomorrow, 7 November 2024 (the "Cancellation").

 

Following the Cancellation, the issued share capital of the Company will
consist of 331,206,012 Ordinary Shares. Each Ordinary Share carries one vote
and there are no shares held in treasury. Therefore, the total number of
voting rights in the Company following Cancellation tomorrow will be
331,206,012 and this figure may be used by shareholders as the denominator for
the calculations by which they can determine if they are required to notify
their interest in, or a change of their interest in the Company under the
Financial Conduct Authority's Disclosure and Transparency Rules.

 

Capitalised terms used in this announcement have the meanings given to them in
the Fundraising Announcement, unless the context provides otherwise.

 

The person responsible for making this Announcement on behalf of the Company
is James McCullough, Chief Executive Officer.

 

 

For further information, please contact:

 

 Renalytix Plc                                                                www.renalytix.com (http://www.renalytix.com)

 James McCullough, CEO                                                        Via Walbrook PR

 Stifel Nicolaus Europe Limited (Nominated Adviser and Joint Broker)          Tel: 020 7710 7600

 Nicholas Moore / Nick Harland / Ben Good

 Oberon Capital (Joint Broker and Sole Bookrunner)                            Tel: 020 3179 5300

 Mike Seabrook / Nick Lovering / Jessica Cave

 Walbrook PR Limited                 Tel: 020 7933 8780 or renalytix@walbrookpr.com

                                   (mailto:renalytix@walbrookpr.com)
 Alice Woodings

                                     Mob: 07407 804 654

 CapComm Partners                    Tel: 415-389-6400 or investors@renalytix.com (mailto:investors@renalytix.com)

 Peter DeNardo

 

 

About Renalytix plc

Renalytix (LSE: RENX) (OTCQB: RNLXY) is an artificial intelligence enabled
in-vitro diagnostics and laboratory services company that is the global
founder and leader in the field of bioprognosis™ for kidney health. In late
2023, our kidneyintelX.dkd test was recognized as the first and only
FDA-authorized prognostic test to enable early-stage CKD (stages 1-3b) risk
assessment for progressive decline in kidney function in T2D patients. By
understanding how disease will progress, patients and clinicians can take
action earlier to improve outcomes and reduce overall health system costs. For
more information, visit www.renalytix.com
(https://www.globenewswire.com/Tracker?data=g2rinqbAgg-q5Zua64QfEh_ImbC7cxpKB9fMEOz3nEgvr6IRtzAZxj77HJRk18dPdtyNTnCS5wIJ1D5jW3xgasJVSc2vtdKOkE7HOw0-TGX3cjSHd3i_CzFCyLZWUcSKJ8HLs45taXYF90tcW2H5jvJQ66-ptubg5SflXxITasXe8SzRw4G-CC8UkUEiwPPxyMy0tKineVUS68YuLWDU-xoRT_xA0mQEJiSlXcxjS4LOlrRcqdgIF2u9l4n8MGLypRT141E4e4yN-23wvBu55Q==)
.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TVRBFBITMTBMBAI